No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
LLY Eli Lilly and Co
- 820.340
- +5.280+0.65%
Close May 31 16:00 ET
- 818.980
- -1.360-0.17%
Post 19:59 ET
779.66BMarket Cap120.82P/E (TTM)
826.210High811.100Low4.47MVolume818.800Open815.060Pre Close3.66BTurnover0.47%Turnover Ratio141.44P/E (Static)950.41MShares826.21052wk High60.85P/B777.84BFloat Cap429.12852wk Low4.69Dividend TTM948.20MShs Float826.210Historical High0.57%Div YieldTTM1.85%Amplitude5.294Historical Low819.130Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
SA Asks: Which Weight-loss Stocks Should Investors Be Watching?
FDA Oncology Chief Says International Clinical Trials Should Be Priority
'Stick With What's Working' as Markets Head Into June Trade: Fundstrat's Tom Lee
Express News | Eli Lilly : Data Demonstrated Promising Monotherapy Activity With Olomorasib Across a Range of Kras G12C-Mutant Solid Tumors
Updated Data From the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients...
Updated Data From the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO Annual Meeting
Data demonstrated promising monotherapy activity with olomorasib across a range of KRAS G12C-mutant solid tumors, including non-small cell lung cancer, and a tolerability profile in combination with p
Comments
$Viking Therapeutics(VKTX.US$ yes company very cheap considering how much total market valuations the other three companies have achieved from just GLP-1 market (Obesity) contribution alone
$Eli Lilly and Co(LLY.US$ easily 400+ Billion valuation from Obesity drug
$Novo-Nordisk A/S(NVO.US$ 50-100 Billion if not wrong
$Amgen(AMGN.US$ 20+ Billion on no data yet
$Eli Lilly and Co(LLY.US$ easily 400+ Billion valuation from Obesity drug
$Novo-Nordisk A/S(NVO.US$ 50-100 Billion if not wrong
$Amgen(AMGN.US$ 20+ Billion on no data yet
1
1
In the last 18 months, $Eli Lilly and Co(LLY.US$ 's mkt cap has moved from $340B to roughly $770B today, there has to be close to $300-$400B attributed to GLP-1, agree? If close to being true, this just simply points to dramatic undervaluation of $Viking Therapeutics(VKTX.US$ with only a $7B mkt cap and what looks like a better GLP-1 franchise. Big pharma wastes a lot of money on stupid deals but this one at $15B is a lay-up. I think a BO happens any day and at a huge premium. Anyone smart enough to buy...
3
Nvidia delighted investors when it announced a 10-for-1 stock split last week. The move may be the start of a trend, as several prominent tech companies trade at prices high enough to tip the scales toward similar splits, according to a note from Bank of America.
The bank highlights 36 S&P 500 companies with stock prices above $500, a level suggesting they may be candidates for splits. $Broadcom(AVGO.US$, $Super Micro Computer(SMCI.US$ , ...
The bank highlights 36 S&P 500 companies with stock prices above $500, a level suggesting they may be candidates for splits. $Broadcom(AVGO.US$, $Super Micro Computer(SMCI.US$ , ...
72
2
$Hims & Hers Health(HIMS.US$ has added GLP-1 weight-loss injections to its portfolio of products.
The injections will have the same active ingredient as $Novo-Nordisk A/S(NVO.US$ ’s Ozempic and Wegovy.
HIMS stock is up by nearly 100% year-to-date.
Hims & Hers added that it would provide branded GLP-1 injections once supply catches up with demand. In the upcoming months, Hims & Hers will work towards providing access to compounded tirzepatide, whic...
The injections will have the same active ingredient as $Novo-Nordisk A/S(NVO.US$ ’s Ozempic and Wegovy.
HIMS stock is up by nearly 100% year-to-date.
Hims & Hers added that it would provide branded GLP-1 injections once supply catches up with demand. In the upcoming months, Hims & Hers will work towards providing access to compounded tirzepatide, whic...
4
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
communicative Axolot : that's cute did you know you can get all the glp1 drugs on Facebook for about 50$ a vial with out a script from hundreds of research grade suppliers?